Results 1 to 10 of about 11,074 (164)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

Case Reports in Oncology, 2016
Background: Alectinib is an oral drug developed for the treatment of patients with fusion gene encoding echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-rearranged non-small cell lung cancer (NSCLC). Here, we present
Tatsuo Kimura, Junko Sowa-Osako, Toshiyuki Nakai, Ayako Ohyama, Tomoya Kawaguchi, Daisuke Tsuruta, Masahiko Ohsawa, Kazuto Hirata   +7 more
doaj   +2 more sources

Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature

Journal of Medical Case Reports, 2018
Background Lung cancer is among the top causes of cancer-related mortality in men and is the second most common cancer after breast cancer in women. There are approximately 234,030 new cases of lung cancer and 154,050 deaths from lung cancer in 2018 as ...
P Ramachandran, R Morcus, M Tahir, I Onukogu, B Spinowitz, Jen C Wang   +5 more
doaj   +2 more sources

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis [PDF]

Biomolecules & Biomedicine, 2021
Most advanced non-small cell lung cancer (NSCLC) patients are accompanied by brain metastasis which is the major cause of increased mortality. The fusion rearrangement of anaplastic lymphoma kinase (ALK) gene is an important feature of brain metastasis ...
Xu Feng, En-Shi Xu
doaj   +2 more sources

Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer

Cancer Treatment and Research Communications, 2021
We present here a case of ALK-positive lung adenocarcinoma that has been started on Alectinib. Treatment has been initiated at the recommended initial dose, but it subsequently required a dose adjustment following adverse drug events.
Danielle Benedict Sacdalan, Josephine Anne Lucero   +1 more
doaj   +1 more source

First-Line Treatment of ALK-Positive NSCLC

healthbook TIMES. Oncology Hematology, 2019
Non-small cell lung cancer (NSCLC) patients with rearrangements in the anaplastic lymphocyte kinase (ALK) gene are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) like alectinib. Here, the case of a 77-year-old male patient with newly diagnosed
Hasna Bouchaab
doaj   +2 more sources

Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC

JTO Clinical and Research Reports
Introduction: Despite receiving alectinib therapy, patients with ALK-positive NSCLC remain at risk of central nervous system (CNS) progression. Our retrospective study aimed to identify baseline clinical and molecular factors associated with the risk of ...
Lianxi Song, MD, Huan Yan, MD, Qinqin Xu, MD, Chunhua Zhou, MD, Juan Liang, MD, Shaoding Lin, MD, Ruiguang Zhang, MD, Juan Yu, MD, Yang Xia, MD, Nong Yang, MD, Liang Zeng, MD, Yongchang Zhang, MD   +11 more
doaj   +1 more source

Successful treatment with crizotinib after alectinib-induced interstitial lung disease

SAGE Open Medical Case Reports, 2021
Although alectinib is a well-tolerated and highly effective inhibitor of a second-generation anaplastic lymphoma kinase, special attention should be paid to the possibility of potentially severe and fatal adverse events such as interstitial pneumonia. We
Ning Zhu, Shanhong Lin, Lei He, Linfeng Wang, Weiliang Kong, Chao Cao   +5 more
doaj   +1 more source

Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report

Current Problems in Cancer: Case Reports, 2022
Background: Anaplastic Lymphoma Kinase (ALK) inhibitors are tyrosine kinase inhibitors used as molecular-targeted therapy for non-small cell lung cancers (NSCLC) harbouring ALK translocations.
Robina Aerts, Jan Brijs, Tine Van Nieuwenhuyse, Mariëlle Beckers, Christophe Dooms, Els Wauters, Kristiaan Nackaerts   +6 more
doaj   +1 more source

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

Frontiers in Oncology, 2023
BackgroundAlectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion.
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Alwin D. R. Huitema, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken   +23 more
doaj   +1 more source

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

JTO Clinical and Research Reports
Introduction: Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced ALK-positive NSCLC, consistent
Caicun Zhou, MD, PhD, You Lu, MD, Sang-We Kim, MD, PhD, Thanyanan Reungwetwattana, MD, Jianying Zhou, MD, Yiping Zhang, MD, Jianxing He, MD, PhD, Jin-Ji Yang, MD, Ying Cheng, MD, Se-Hoon Lee, MD, PhD, Jianhua Chang, MD, Jian Fang, MD, Zhe Liu, PhD, Lilian Bu, MSc, Li Qian, MD, Tingting Xu, MD, Venice Archer, MB ChB, MSc, Magalie Hilton, MSc, Mingzhu Zhou, MSc, Li Zhang, MD   +19 more
doaj   +1 more source